By Michael Ollove, Stateline.org
WASHINGTON — If used widely, a new generation of antiviral drugs has the potential to wipe out the deadly hepatitis C virus in the United States. But the high price of the drugs might prevent their use in prisons, which house as many as one-third of those who are infected.
The drugs cost anywhere from about $65,000 to $170,000 for a single course of treatment — between three and nine times more than earlier treatments. Ronald Shansky, former medical director of the Illinois prison system and founder of the Society of Correctional Physicians, described that price as “extortionarily high, criminal.”
Fair or not, the cost of the new drugs is likely to keep them out of reach for most infected prisoners. To put the price in perspective, the average annual cost for states to house an inmate is $29,141. The minimal cost of treating a single patient with the new hepatitis C drugs is more than double that amount.
The two manufacturers, Janssen Therapeutics and Gilead Sciences, defend their prices, saying their medications represent a huge advance in treatment.
Hepatitis C progresses slowly, but without treatment it can lead to liver failure and death. Given the grave consequences, the availability of the new drugs creates a wrenching dilemma for correctional systems. With more expensive specialty drugs expected to enter the marketplace in the coming years, the decisions will only get more vexing.
“The question is if you have a cure rate of approximately 90 percent or higher, is there justification for not treating someone other than the huge cost?” asked Jack Beck, director of the Prison Visiting Project of the Correctional Association of New York, “But no state has the budget to absorb those huge costs.”
Approval of the new drugs late last year by the U.S. Food and Drug Administration marked a welcome advance in the treatment of hepatitis C. It is estimated that as many as 5.5 million Americans have the disease. At least twice as many carry the virus but don’t know it, since it can remain asymptomatic for decades.
A new study estimates that 1.86 million people with antibodies to the virus were incarcerated during the study year. The virus is passed most frequently through needle-sharing during intravenous drug use and tattooing, which are common in prisons. The study estimated the prevalence rate of hepatitis C in state correctional facilities to be about 17 percent, compared with a rate of 1 percent to 2 percent in the general population.
The new drugs, simeprevir (marketed as Olysio by Janssen Therapeutics, a division of Johnson & Johnson) and sofosbuvir (sold as Sovaldi by Gilead Sciences), have a cure rate of 95 percent or better in some clinical studies, compared with 45 percent for previous medications. Unlike the alternatives, simeprevir and sofosbuvir cause only mild side effects, and can be taken orally. Furthermore, patients only have to take them for 12 to 24 weeks, compared with at least 48 weeks for the previous treatments.
Yet at approximately $1,000 per pill, the cost is likely to prove a challenge for the entire health care system, including Medicaid, Medicare and private insurance companies. The difference is that prisons are constitutionally bound to provide adequate health care to prisoners.
States and municipalities typically pay for prisoner health care out of their corrections budgets. When effective HIV treatments emerged in the late 1990s, those budgets grew to accommodate the cost of the drugs, said Edward Harrison, president of National Commission on Correctional Health Care, which sets standards for prisoner health care.
But the new hepatitis C medications present a much bigger challenge. “The prevalence of HCV (hepatitis C) is 10 times greater than HIV and the cost of treatment is probably 10 times greater than a year’s worth of treating HIV,” said Anne Spaulding of Emory University, one of the leading researchers on hepatitis C in prisons.
“It’s something that everyone is grappling with right now,” said Lara Strick, the infectious disease consultant to the Washington State Department of Corrections. “I can’t say I or anyone else now knows the right answers.”
Whether states have the option to not treat prisoners with the new drugs is open to debate. Under the Eighth Amendment, prisons are barred from demonstrating “deliberate indifference” to the well-being of prisoners. But Gabriel Eber, staff counsel of the ACLU National Prison Project, said that mandate falls far short of a requirement to provide optimum care. Most states don’t even provide prisoners with the old, less expensive hepatitis C drugs, and only 12 states screen inmates for the disease.
The courts generally have dismissed prisons’ pleas of poverty as an excuse for not providing care. At the same time, however, they tend to defer to prisons on the question of what constitutes “medical necessity.”
As a result, Eber said, “I don’t see (the new treatments) being widely available until costs come down.”
Photo: x1klima via Flickr
